Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 12 Nov 2026
Standard addition

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.

Weekly pemvidutide improved markers of liver inflammation and fibrosis in adults with fatty liver disease, offering hope for slowing liver damage progression.

This multicenter randomized double-blind phase 2b trial examined Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis, suggesting continued improvement in liver health.

What the study was

Study design
Multicenter randomized double-blind phase 2b trial
Sample size
41
Category
Treatment Innovation
Maturity
Validated
Journal
The lancet. Gastroenterology & hepatology

Why it surfaced

Retained after review of PubMed metadata and abstract because its multicenter randomized double-blind phase 2b trial directly informs cardiovascular-metabolic; scoring was capped conservatively for design and evidence maturity.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.